Scott Lentini
Senior Principal Scientist at Eli Lilly
- Role
- Sr Principal Scientist Peptide and Antibody Bioconjugation at Eli Lilly and Company
- Location
- Cambridge, MA, US
- LinkedIn followers
- 500 followers
About Scott Lentini
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines. Alnylam\'s pipeline of investigational RNAi therapeutics is focused in 3 Strategic Therapeutic Areas (STArs): Genetic Medicines, with a broad pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases; and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics that address the major global health challenges of hepatic infectious diseases.RNAi (RNA interference) is a revolution in biology, representing a breakthrough in understanding how genes are turned on and off in cells, and a completely new approach to drug discovery and development. Its discovery has been heralded as \"a major scientific breakthrough that happens once every decade or so,\" and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery today which was awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi is a natural process of gene silencing that occurs in organisms ranging from plants to mammals. By harnessing the natural biological process of RNAi occurring in our cells, the creation of a major new class of medicines, known as RNAi therapeutics, is on the horizon. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam\'s RNAi therapeutic platform, target the cause of diseases by potently silencing specific mRNAs, thereby preventing disease-causing proteins from being made. RNAi therapeutics have the potential to treat disease and help patients in a fundamentally new way.
Experience
Sr Principal Scientist Peptide and Antibody Bioconjugation
Jan 2025 — Present · Boston, MA, US
Education
University of Massachusetts Amherst
BS, Chemistry
1999 — 2003
Skills
- High Throughput Screening
- Peptides
- In Vivo
- Organic Chemistry
- Peptide Synthesis
- Drug Discovery
- Organic Synthesis
- Hplc
- Assay Development
- Small Molecules
- Clinical Development
- Lifesciences
- Purification
- Protein Chemistry
- Drug Design
- Lc-Ms
- Chemistry
- Biotechnology
- Drug Development
- Cancer
- Biopharmaceuticals
- Fluorescence Microscopy
- Cell
- In Vitro
- Mass Spectrometry
- Medicinal Chemistry
- Oncology
- Biophysics
- Biomarkers
Find verified contacts for anyone on LinkedIn
Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.
Free plan included · No credit card required
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.